Open Medicine EU

The Limits of Psychiatry?

This post is a slight digression from the core themes of the blog but it does have some connection to medicine and science, or at least to how not to do it. I dislike reading in the media quotes from psychiatrists offering a quasi-diagnosis of living people whom they have never met. There was a… » read more

Posted by Jim Murray

How Dreadful

I’ve just read on the Fierce Pharma website that the FDA proposes to test a drug imported from the UK that is to be used in the execution of prisoners on death row in the U.S. I suppose there is a kind of grim logic in trying to ensure that the drug does not cause… » read more

Posted by Jim Murray

English laws on libel stifle scientific debate, not only in England but around the world. There are three problems: – English law is more favourable to the plaintiff than the laws in many other countries. – The costs of defending a libel action in London are very high – from 100 000 euros for starters… » read more

Posted by Jim Murray

As mentioned in my previous post, the European Medicines Agency has announced a new transparency policy. Not before time. -In an article in the BMJ in April this year the authors cited earlier research indicating that the EMA was very much less transparent that the FDA in a number of key areas, including information on… » read more

Posted by Jim Murray

The European Medicines Agency announced today (30th November) a new transparency policy that would widen access to documents held by the agency. This is good news (apart from the fact that I had to scrap a post I had just finished, attacking the old policy…) I believe that the agency will be more transparent under… » read more

Posted by Jim Murray

AstraZeneca on Transparency

Interesting report on FoxBusiness News ( I know, I know). The global pharmaceuticals industry must become more transparent if it is to rebuild public trust in the sector, AstraZeneca PLC’s chief executive said Wednesday. David Brennan told a gathering of drug sector leaders that industry stockholders need to collaborate to collectively address the world’s healthcare… » read more

Posted by Jim Murray

Prequel to Seroquel

How is science made in a pharmaceutical company, when billions of Euros may depend on the outcome of a scientific experiment? A partial, if incomplete, glimpse at the process can be seen in the documents released last year in a court case in the US on the AstraZeneca medicine Seroquel. (Seroquel is a “blockbuster” drug,… » read more

Posted by Jim Murray